OMass Therapeutics is Drug Discovery in United Kingdom that focus on pharmaceutical clients business. Founded in 2016. They cover business area such as developer, novel medicine, access, native mass spectrometry, sophisticated instrumentation, expertise, house, complex protein assembly, their interaction, biotechnology, pharmaceutical client, challenge drug target, biotherapeutic.
2016
( 8 years old in 2024 )
Pharmaceutical Clients
-
The Schrödinger Building
Heatley Road, The Oxford Science Park
Oxford OX4 4GE
England, United Kingdom
Private
developernovel medicineaccessnative mass spectrometrysophisticated instrumentationexpertisehousecomplex protein assemblytheir interactionbiotechnologypharmaceutical clientchallenge drug targetbiotherapeutic
* We use standard office opening hours in near OMass Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
OMass Therapeutics is Drug Discovery business from United Kingdom that founded in 2016 (8 years old in 2024), OMass Therapeutics business is focusing on Pharmaceutical Clients.
OMass Therapeutics headquarter office and corporate office address is located in The Schrödinger Building Heatley Road, The Oxford Science Park Oxford OX4 4GE England, United Kingdom.
OMass Therapeutics was founded in United Kingdom.
In 2024, OMass Therapeutics is currently focus on pharmaceutical clients sector.
Above is snippet of Google Trends for "pharmaceutical clients" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with OMass Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
